Evidence map›Paper›PMID 39935753›Full record

ArticleContemporary oncology (Poznan, Poland)2024

Quality of life of patients treated for stage IV breast cancer. Multidimensional assessment and examination of determining factors.

Juan Ignacio Arraras, Jose Juan Illarramendi, Ana Manterola, Uxue Zarandona, Berta Ibañez, Andrew Bottomley, Lucia Teijeira, Ignacio Visus, Susana de la Cruz, Marta Barrado and 1 more

Abstract read
In one paragraph

Article in Contemporary oncology (Poznan, Poland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Exploring the lived experiences of women with metastatic breast cancer and their HRQoL questionnaire preferences: a qualitative study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Juan Ignacio ArrarasMedical Oncology Department, Hospital Universitario de Navarra, Pamplona, Spain.
Jose Juan IllarramendiMedical Oncology Department, Hospital Universitario de Navarra, Pamplona, Spain.
Ana ManterolaRadiotherapeutic Oncology Department, Hospital Universitario de Navarra, Pamplona, Spain.
Uxue ZarandonaRadiotherapeutic Oncology Department, Hospital Universitario de Navarra, Pamplona, Spain.
Berta IbañezMethodology Unit, Navarrabiomed, RICAPPS, Spain.
Andrew BottomleyBottomley Consulting Group, Brussels, Belgium.
Lucia TeijeiraMedical Oncology Department, Hospital Universitario de Navarra, Pamplona, Spain.
Ignacio VisusRadiotherapeutic Oncology Department, Hospital Universitario de Navarra, Pamplona, Spain.
Susana de la CruzMedical Oncology Department, Hospital Universitario de Navarra, Pamplona, Spain.
Marta BarradoRadiotherapeutic Oncology Department, Hospital Universitario de Navarra, Pamplona, Spain.
Ruth VeraMedical Oncology Department, Hospital Universitario de Navarra, Pamplona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Metastatic breast cancer (MBC) can profoundly impact patients' lives. The health-related quality of life (HRQOL) of MBC metavivors remains a paramount concern. This study exa-mined the multifaceted aspects of HRQOL in MBC metavivors. Material and methods: Ninety-eight participants with over 4 years of meta-static disease were evaluated using the European Organisation for Research and Treatment of Cancer (EORTC) questionnaires QLQ-C30, QLQ-BR42 and QLQ-BM22 alongside the Assessment of Survivor Concerns (ASC) questionnaire. Results: HRQOL scores were high (> 80/100 points) in some HRQOL areas, including role, cognitive and social functioning and breast symptoms. Moderate limitations (> 30 points) occurred in global QOL and financial impact (QLQ-C30); sexual functioning, sexual enjoyment, future perspective, breast satisfaction, upset by hair loss, skeletal symptoms, and weight gain (QLQ-BR42); and psychosocial aspects of QLQ-BM22. Worries were moderate in the two ASC factors (6.8 and 5.3) and the global scale (11.7). The multivariate model that best explains high risk of low global QOL included limiting comorbidity, financial impact, cancer worry and role functioning ( Conclusions: This study shows that MBC metavivors adapted well to their situation and underscores the persistent HRQOL challenges they face. In-depth analysis of the QLQ-C30 glo-bal score highlights the need to address not only medical aspects but also integrated psychosocial and economi-cal support in MBC metavivor care. HRQOL variations across metastatic sites underscore the need to tailor interventions to address site-specific challenges.

Indexed as

breast neoplasmsmetavivorsneoplasm metastasisquality of life

Identifiers

PMID39935753
PMCPMC11809568

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.